Last updated: June 22, 2026
Litigation summary and analysis for Gilead Sciences, Inc. v. Aspiro Pharma Ltd., 2:25-cv-13936
What does the docket number 2:25-cv-13936 cover, and what parties are involved?
Case: Gilead Sciences, Inc. v. Aspiro Pharma Ltd.
Court docket: 2:25-cv-13936
Caption (core parties): Gilead Sciences, Inc. (plaintiff) vs Aspiro Pharma Ltd. (defendant)
What a high-stakes read requires: A litigation summary for an IP case must identify (1) the asserted patent(s), (2) the procedural posture (complaint filed, TRO/PI sought, answer, Rule 12 motions, claim construction, discovery schedule), (3) the FDA regulatory hook if it is an ANDA/BLA Paragraph IV case, and (4) settlement or exclusivity outcomes.
No case-specific record (complaint, patent list, filing dates, parties’ addresses, and any orders) is provided in the prompt. Under this task’s constraint, a complete and accurate litigation summary cannot be produced from the docket number alone.
What patents did Gilead assert against Aspiro in this case?
Required elements: asserted U.S. patents, asserted claims, and whether the case is tied to an ANDA/BLA notice (e.g., Paragraph IV).
Status based on provided inputs: Not available.
What is the procedural posture in 2:25-cv-13936 (motions, hearings, scheduling, and any injunction requests)?
Required elements: docket events and dates (summons/service, complaint, motion to dismiss, PI/TRO, answers, Markman, scheduling order).
Status based on provided inputs: Not available.
Is this an ANDA/Paragraph IV or a different IP theory (method-of-use, formulation, biologics, or trade secret)?
Required elements: FDA pathway, product name, ANDA application number, BLA if relevant, and statutory basis (e.g., 35 U.S.C. § 271(e)(2)).
Status based on provided inputs: Not available.
What arguments is Gilead likely making, and what would Aspiro likely respond?
Required elements: claims asserted, infringement theory, invalidity defenses (anticipation/obviousness/§101/§112), and any design-around around formulation or method steps.
Status based on provided inputs: Not available.
How could this litigation affect generic or branded market entry timelines?
Required elements: whether an FDA approval is pending, any 180-day exclusivity triggers, whether a settlement agreement exists, and whether the court entered a stay or injunction.
Status based on provided inputs: Not available.
What settlement terms or consent judgments are on the docket?
Required elements: settlement agreement date, covenants not to sue, permitted launch dates, “no-redistribution” or supply restrictions, and any dismissal-with-prejudice language.
Status based on provided inputs: Not available.
Which jurisdictions and courts are implicated beyond the federal case?
Required elements: related district court cases, PTAB challenges, International Trade Commission, state proceedings, or parallel Hatch-Waxman litigation.
Status based on provided inputs: Not available.
Key takeaways
A docket number alone is not sufficient to produce a complete, accurate litigation summary and analysis for Gilead Sciences, Inc. v. Aspiro Pharma Ltd. (2:25-cv-13936). No patent assertions, FDA linkage, procedural history, orders, or settlement terms are contained in the prompt, so no high-integrity, business-usable litigation analysis can be generated.
FAQs
What is the statutory basis for Gilead’s claims in 2:25-cv-13936?
Not available from provided inputs.
Did the case seek a preliminary injunction or temporary restraining order?
Not available from provided inputs.
What FDA application (ANDA/BLA) is tied to the litigation, if any?
Not available from provided inputs.
Are any patents asserted in this case listed on the Orange Book?
Not available from provided inputs.
Is Aspiro Pharma the first Paragraph IV filer for the relevant product?
Not available from provided inputs.
References
Not available because no case documents or cited sources were provided.
